Lyell Immunopharma reported revenue of $0.00M and net income of -$44.90M for the quarter ended Jun 2026, down 50.0% year over year. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 11.99M | 6.80M | 12.27M | 12.36M | 12.46M | 12.48M | 12.48M | 12.55M | 12.59M | 12.70M | 12.75M | 12.80M | 12.83M | 14.74M | 14.76M | 14.83M | 19.29M | 17.09M | 23.33M | 23.40M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 2.75M | 2.82M | 0.55M | 35.74M | 0.00M | 48.39M | 0.07M | 0.03M | 0.03M | 0.01M | 0.00M | 0.01M | 0.03M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M | |||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 31.43M | 19.29M | 35.83M | 43.72M | 41.61M | 38.03M | 44.63M | 47.47M | 43.85M | 46.99M | 43.17M | 40.26M | 39.50M | 48.67M | 43.45M | 34.86M | 28.17M | 52.20M | 36.60M | 39.52M | |||||
| Selling, General & AdministrativeSG&A | 21.24M | 31.87M | 34.42M | 30.45M | 26.08M | 26.35M | 19.28M | 19.03M | 15.51M | 13.17M | 13.49M | 12.26M | 11.77M | 14.52M | 14.05M | 9.79M | 10.69M | 10.62M | 9.55M | 9.58M | |||||
| Other Operating ExpensesOther Opex | 0.76M | 0.80M | 1.12M | 1.17M | 1.25M | 1.21M | 1.29M | 0.57M | 0.29M | 0.64M | 1.09M | 0.98M | 0.73M | 0.51M | 0.12M | -1.06M | 1.59M | 1.50M | 1.90M | 1.76M | |||||
| Operating ExpensesOpex | 51.92M | 50.36M | 69.13M | 73.00M | 66.44M | 63.17M | 62.62M | 65.93M | 59.06M | 59.52M | 55.58M | 51.54M | 50.54M | 201.16M | 57.37M | 47.15M | 37.27M | 127.65M | 44.26M | 47.34M | |||||
| Operating IncomeOp. Inc | -49.16M | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | |||||
| EBIT | -49.16M | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.27M | -2.72M | -4.98M | -1.75M | 2.25M | 15.43M | 4.50M | 5.26M | 6.61M | 7.08M | 6.82M | 6.36M | 5.96M | 4.92M | 3.86M | 3.28M | 3.27M | 2.68M | 2.19M | 2.18M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | -0.04M | 0.04M | -0.01M | -1.07M | 2.93M | 1.10M | -0.33M | 1.58M | -0.51M | 1.09M | -0.65M | -0.04M | 4.29M | 1.31M | 1.18M | -4.86M | -15.76M | 17.91M | 0.40M | |||||
| Non Operating IncomeNon Op. Inc. | 0.29M | -36.17M | 0.43M | 0.94M | -3.82M | 6.39M | -4.40M | 2.02M | 8.19M | 6.58M | -5.09M | 5.72M | 5.92M | 9.21M | 5.17M | 4.46M | -1.59M | -13.08M | 20.11M | 2.58M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -48.89M | -50.26M | -73.55M | -39.01M | -64.19M | 0.64M | -58.06M | -60.64M | -52.43M | -52.42M | -48.76M | -45.16M | -44.54M | -196.23M | -53.51M | -43.86M | -33.99M | -124.97M | -42.07M | -45.15M | |||||
| Profit After TaxPAT | -49.01M | -85.26M | -73.12M | -38.07M | -71.90M | -6.00M | -66.96M | -63.89M | -50.85M | -52.93M | -60.98M | -45.81M | -44.58M | -191.94M | -52.33M | -42.78M | -38.85M | -140.68M | -24.40M | -44.90M | |||||
| Income from Continuing OperationsIncome (Continuing) | -48.89M | -50.26M | -73.55M | -39.01M | -64.19M | 0.64M | -58.06M | -60.64M | -52.43M | -52.42M | -48.76M | -45.16M | -44.54M | -196.23M | -53.51M | -43.86M | -33.99M | -124.97M | -42.07M | -45.15M | |||||
| Consolidated Net IncomeConsol Net Inc. | -48.89M | -50.26M | -73.55M | -39.01M | -64.19M | 0.64M | -58.06M | -60.64M | -52.43M | -52.42M | -48.76M | -45.16M | -44.54M | -196.23M | -53.51M | -43.86M | -33.99M | -124.97M | -42.07M | -45.15M | |||||
| Income towards Parent CompanyParent Net Inc | -48.89M | -50.26M | -73.55M | -39.01M | -64.19M | 0.64M | -58.06M | -60.64M | -52.43M | -52.42M | -48.76M | -45.16M | -44.54M | -196.23M | -53.51M | -43.86M | -33.99M | -124.97M | -42.07M | -45.15M | |||||
| Net Income towards Common StockholdersNet Income | -48.89M | -50.26M | -73.55M | -39.01M | -64.19M | 0.64M | -58.06M | -60.64M | -52.43M | -52.42M | -48.76M | -45.16M | -44.54M | -196.23M | -53.51M | -43.86M | -33.99M | -124.97M | -42.07M | -45.15M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -4.08 | -7.40 | -6.02 | -3.17 | -5.17 | 0.05 | -4.65 | -4.85 | -4.17 | -4.18 | -3.84 | -3.54 | -3.48 | -15.01 | -3.63 | -2.97 | -1.86 | -7.31 | -1.92 | -1.93 | |||||
| EPS (Diluted) | -4.08 | -7.40 | -6.02 | -3.17 | -5.17 | 0.05 | -4.65 | -4.85 | -4.17 | -4.18 | -3.84 | -3.54 | -3.48 | -15.01 | -3.63 | -2.97 | -1.86 | -7.31 | -1.92 | -1.93 | |||||
| Shares Outstanding | 11.97M | 6.80M | 12.21M | 12.32M | 12.42M | 12.35M | 12.48M | 12.51M | 12.57M | 12.55M | 12.71M | 12.77M | 12.82M | 13.07M | 14.75M | 14.79M | 18.27M | 17.09M | 21.88M | 23.36M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 11.97M | 6.80M | 12.21M | 12.32M | 12.42M | 12.35M | 12.48M | 12.51M | 12.57M | 12.55M | 12.71M | 12.77M | 12.82M | 13.07M | 14.75M | 14.79M | 18.27M | 17.09M | 21.88M | 23.36M | |||||
| EBITDA | -49.16M | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M |